

REGISTERED CHARITY NUMBER: 1143642

**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2023
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor

**Contents of the Financial Statements
for the Year Ended 31 August 2023**

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8 to 14

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

The trustees present their report with the financial statements of the charity for the year ended 31 August 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

OBJECTIVES AND ACTIVITIES

Objectives and aims

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Significant activities

Main activities undertaken

The activities that supported the objectives of the Charity during the year were:

- The provision of a website providing advice, information and support.
- The provision of a private Facebook group which has over 1000 members from across the world. Patients are based in predominantly English speaking countries with members worldwide.
- We provided practical as well as emotional support to patients and families through our grant programme and have given financial support to fifteen families this year.
- The ongoing provision of a Buddy Scheme to provide one to one support to patients and caregivers around the world.
- The provision of a £50,000 Grant to the Norwegian GNAS vaccine trial at Oslo University.

In order to support our patients and their caregivers we have

- Provided access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. We contributed £15,000 during this financial year.
- Supported fifteen families with financial grants.
- Given ward toiletries to The Christie and Basingstoke.
- Run a programme of regional meetups for patient and caregivers.
- Contributed £700 towards the cost of individual online physiotherapy sessions for a group of seven patient.

In order to promote awareness of pseudomyxoma peritonei, Trustees have:

- Attended various online sessions hosted by the Small Charities Coalition, National Voices and Findacure
- Attended the Cancer52 meetings online
- Attended relevant EuroPMP meetings
- Promote Rare Disease Day (28th February 2023)
- Presented at the joint global webinar with ACPMP and PALS to promote PMP Awareness Month (August)
- Paid for six NHS staff to undertake a course on how to deliver Hyperthermic intraperitoneal chemotherapy.

As part of our charitable aims and objectives we have contributed funds to the following research programmes during the year to 31 August 2023:

- £11,000 to the Christie Hospital Prehabilitation research project
- £50,000 to the Norwegian GNAS Vaccine Trial at Oslo University Oslo University GNAS research programme.

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives.

We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust.

We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations which we demonstrated through this year with our committed registration with the Fundraising Regulator.

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

ACHIEVEMENT AND PERFORMANCE

Charitable activities

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters we have received £87,687 in donations and other income. We are indebted to all of our fundraisers and their families and friends for their generosity.

Our Facebook support group goes from strength to strength and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie in Manchester which allows us to better support patients and identify research opportunities.

Once again we are able to retain our status with the Great NonProfits organisation.

FINANCIAL REVIEW

Financial position

We are extremely pleased that we have total funds of £228,974 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stock and shares.

Reserves policy

Through prudence in our activities, we are now in a position to be able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 12 months. With more appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community. During the year to 31 August 2023, 12 months' running costs equated to £15,108, whilst reserves at the period end totalled £228,890 and reserves excluding designated funds totalled £111,390.

We have designated expenditure as at the year ended 31 August 2023 of £117,500 which will be spent in accordance with our charitable objectives, aims and activities which are detailed in the Trustee report. All opportunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.

FUTURE PLANS

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2023/2024:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
- We will have discussions with the Christie Hospital in Manchester to continue financially supporting the prehabilitation study.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
- We will continue to closely monitor the Norwegian GNAS research programme.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Pseudomyxoma Survivor

Report of the Trustees for the Year Ended 31 August 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

The Friends of the charity this year that warrant special mention include the following supporters:

- The Alan Boswell Group, who kindly donated £5000 via an employee nomination scheme.
 - Karen's Big Smiles charity trust who kindly donated £10,000 from their final distribution following the closure of the charity.
 - Rebecca Currie who raised awareness and funds, through her school, in celebration of her amazing Mum.
- There are far too many fundraisers and donors to name individually this year but a very special thank you to all those who donated to a successful 'GoFundme' campaign to raise money for the Norwegian research programme.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

9 Ilmington Close
Hatton Park
Warwick
CV35 7TL


Trustees

Mrs S Oliver
Mr T Brill (appointed 1.1.23)
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Approved by order of the board of trustees on 8 December 2023 and signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2023.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: 11/12/2023

Pseudomyxoma Survivor

**Statement of Financial Activities
for the Year Ended 31 August 2023**

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		59,363	28,324	87,687	67,193
EXPENDITURE ON					
Raising funds	2	6,963	-	6,963	4,128
Charitable activities	3				
Charitable activities		12,915	-	12,915	10,873
Grant making		30,088	55,000	85,088	15,397
Support costs		1,476	-	1,476	1,656
Total		51,442	55,000	106,442	32,054
NET INCOME/(EXPENDITURE)					
Transfers between funds	11	7,921 (26,676)	(26,676) 26,676	(18,755) -	35,139 -
Net movement in funds		(18,755)	-	(18,755)	35,139
RECONCILIATION OF FUNDS					
Total funds brought forward		247,645	-	247,645	212,506
TOTAL FUNDS CARRIED FORWARD		228,890	-	228,890	247,645


The notes form part of these financial statements

Pseudomyxoma Survivor

Balance Sheet
31 August 2023

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
CURRENT ASSETS					
Debtors	9	140	-	140	180
Cash at bank		230,946	-	230,946	250,141
		231,086	-	231,086	250,321
CREDITORS					
Amounts falling due within one year	10	(2,196)	-	(2,196)	(2,676)
NET CURRENT ASSETS		228,890	-	228,890	247,645
TOTAL ASSETS LESS CURRENT LIABILITIES		228,890	-	228,890	247,645
NET ASSETS		228,890	-	228,890	247,645
FUNDS	11				
Unrestricted funds				228,890	247,645
TOTAL FUNDS				228,890	247,645

The financial statements were approved by the Board of Trustees and authorised for issue on 8 December 2023 and were signed on its behalf by:


Mrs A C Salisbury - Trustee

The notes form part of these financial statements

Pseudomyxoma Survivor

Notes to the Financial Statements for the Year Ended 31 August 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

1. ACCOUNTING POLICIES - continued

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. RAISING FUNDS

Raising donations and legacies

	2023	2022
	£	£
Just Giving	1,422	1,418
Costs of generating funds	5,541	2,710
	<u>6,963</u>	<u>4,128</u>

3. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Grant funding of activities (see note 4) £	Support costs (see note 5) £	Totals £
Charitable activities	12,831	-	84	12,915
Grant making	-	85,088	-	85,088
Support costs	-	-	1,476	1,476
	<u>12,831</u>	<u>85,088</u>	<u>1,560</u>	<u>99,479</u>

4. GRANTS PAYABLE

	2023	2022
	£	£
Grant making	85,088	15,397
	<u>85,088</u>	<u>15,397</u>

5. SUPPORT COSTS

	Governance costs £
Charitable activities	84
Support costs	1,476
	<u>1,560</u>

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

5. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

	Charitable activities	Support costs	2023 Total activities	2022 Total activities
	£	£	£	£
Independent examination	84	1,476	1,560	1,656
	<u>84</u>	<u>1,476</u>	<u>1,560</u>	<u>1,656</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £7,560 (2022 - £8,640) but no other benefits for the year ended 31 August 2023 or other benefits for the year ended 31 August 2022.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2023 nor for the year ended 31 August 2022.

7. STAFF COSTS

There were no staff costs for the year ended 31 August 2023 nor for the year ended 31 August 2022.

The average number of employees during the year was NIL (2022 - NIL).

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	67,193	-	67,193
	<u>67,193</u>	<u>-</u>	<u>67,193</u>
EXPENDITURE ON			
Raising funds	4,128	-	4,128
Charitable activities			
Charitable activities	10,873	-	10,873
Grant making	15,397	-	15,397
Support costs	1,656	-	1,656
	<u>32,054</u>	<u>-</u>	<u>32,054</u>
Total	<u>32,054</u>	<u>-</u>	<u>32,054</u>
NET INCOME	35,139	-	35,139
RECONCILIATION OF FUNDS			
Total funds brought forward	212,506	-	212,506

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £	Restricted funds £	Total funds £
TOTAL FUNDS CARRIED FORWARD	247,645	-	247,645

9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Other debtors	40	-
Prepayments and accrued income	100	180
	<u>140</u>	<u>180</u>

10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Trade creditors	456	1,020
Other creditors	1,740	1,656
	<u>2,196</u>	<u>2,676</u>

11. MOVEMENT IN FUNDS

	At 1.9.22 £	Net movement in funds £	Transfers between funds £	At 31.8.23 £
Unrestricted funds				
General fund	247,645	7,921	(144,176)	111,390
Designated fund	-	-	117,500	117,500
	<u>247,645</u>	<u>7,921</u>	<u>(26,676)</u>	<u>228,890</u>
Restricted funds				
Research fund	-	(26,676)	26,676	-
	<u>-</u>	<u>(26,676)</u>	<u>26,676</u>	<u>-</u>
TOTAL FUNDS	<u>247,645</u>	<u>(18,755)</u>	<u>-</u>	<u>228,890</u>

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

11. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	59,363	(51,442)	7,921
Restricted funds			
Research fund	23,324	(50,000)	(26,676)
Family grants	5,000	(5,000)	-
	<u>28,324</u>	<u>(55,000)</u>	<u>(26,676)</u>
TOTAL FUNDS	<u>87,687</u>	<u>(106,442)</u>	<u>(18,755)</u>

Comparatives for movement in funds

	At 1.9.21 £	Net movement in funds £	At 31.8.22 £
Unrestricted funds			
General fund	212,506	35,139	247,645
TOTAL FUNDS	<u>212,506</u>	<u>35,139</u>	<u>247,645</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	67,193	(32,054)	35,139
TOTAL FUNDS	<u>67,193</u>	<u>(32,054)</u>	<u>35,139</u>

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

11. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.9.21 £	Net movement in funds £	Transfers between funds £	At 31.8.23 £
Unrestricted funds				
General fund	212,506	43,060	(144,176)	111,390
Designated fund	-	-	117,500	117,500
	<u>212,506</u>	<u>43,060</u>	<u>(26,676)</u>	<u>228,890</u>
Restricted funds				
Research fund	-	(26,676)	26,676	-
	<u>-</u>	<u>(26,676)</u>	<u>26,676</u>	<u>-</u>
TOTAL FUNDS	<u>212,506</u>	<u>16,384</u>	<u>-</u>	<u>228,890</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	126,556	(83,496)	43,060
Restricted funds			
Research fund	23,324	(50,000)	(26,676)
Family grants	5,000	(5,000)	-
	<u>28,324</u>	<u>(55,000)</u>	<u>(26,676)</u>
TOTAL FUNDS	<u>154,880</u>	<u>(138,496)</u>	<u>16,384</u>

Restricted funds relate to the provision of a research grant to the Norwegian GNAS vaccine trial at Oslo University and grants provided to families in need.

Transfers between funds

The transfer from general funds to restricted funds relate to an allocation to the Research fund which required additional funding in the year.

The designated fund relates to monies set aside for committed future spending.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

12. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2023.